Studying the pathogenesis of BCR–ABL+ leukemia in mice

被引:0
|
作者
Richard A Van Etten
机构
[1] Harvard Medical School,The Center for Blood Research and Department of Genetics
来源
Oncogene | 2002年 / 21卷
关键词
CML; tyrosine kinase; retrovirus; Philadelphia chromosome;
D O I
暂无
中图分类号
学科分类号
摘要
Animal models of BCR–ABL+ leukemias have provided important new knowledge about the molecular pathophysiology of these diseases, and answered questions that are difficult or impossible to address using BCR–ABL-expressing cell lines or primary Ph+ leukemia samples from patients. The power of mouse models lies in their ability to recapitulate precisely the phenotypes of BCR–ABL+ leukemias in vivo, but this comes at the price of significant complexity. Here I review recent studies of leukemias induced in mice by BCR–ABL with an emphasis on the intricate nature of these diseases and the need for careful pathological and molecular analysis.
引用
收藏
页码:8643 / 8651
页数:8
相关论文
共 50 条
  • [1] Studying the pathogenesis of BCR-ABL+ leukemia in mice
    Van Etten, RA
    ONCOGENE, 2002, 21 (56) : 8643 - 8651
  • [2] Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia
    J Westermann
    J Kopp
    I Körner
    G Richter
    Z Qin
    T Blankenstein
    B Dörken
    A Pezzutto
    Bone Marrow Transplantation, 2000, 25 : S46 - S49
  • [3] The immunogenicity of BCR/ABL+ cells is dominated by BCR/ABL-regulated antigens and is impaired by the inhibition of BCR/ABL kinase activity.
    Scheich, Florian
    Peschel, Christian
    Bernhard, Helga
    BLOOD, 2006, 108 (11) : 624A - 624A
  • [4] ACUTE-LEUKEMIA IN BCR/ABL TRANSGENIC MICE
    HEISTERKAMP, N
    JENSTER, G
    TENHOEVE, J
    ZOVICH, D
    PATTENGALE, PK
    GROFFEN, J
    NATURE, 1990, 344 (6263) : 251 - 253
  • [5] CHARACTERIZATION OF BCR/ABL+ NATURAL-KILLER (NK) CELLS FROM PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
    SILLA, L
    PINCUS, SM
    LOCKER, JD
    OLIVERI, DO
    GLOVER, J
    ELDER, E
    DONNENBERG, AD
    WHITESIDE, TL
    BLOOD, 1993, 82 (10) : A382 - A382
  • [6] BCR/ABL and leukemia
    Butturini, A
    Arlinghaus, RB
    Gale, RP
    LEUKEMIA RESEARCH, 1996, 20 (06) : 523 - 529
  • [7] The RALGEF Pathway Contributes to the Pathogenesis of Chronic Myelogenous Leukemia by BCR/ABL
    Fredericks, Jessica
    Parikh, Chaitali
    Subrahmanyam, Ramesh
    Ren, Ruibao
    BLOOD, 2008, 112 (11) : 1101 - 1101
  • [8] Pre-/Post-HSCT Imatinib Improves Survival of Childhood with BCR/ABL+ Acute and Chronic Leukemia
    Pei, Fuyu
    Li, Qi
    Xu, Wenfeng
    Peng, Zhiyong
    Wu, Xuedong
    He, Yuelin
    Feng, Xiaoqin
    Li, Chunfu
    BLOOD, 2014, 124 (21)
  • [9] HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
    Tri Nguyen
    Dai, Yun
    Attkisson, Elisa
    Kramer, Lora
    Jordan, Nicholas
    Nguyen Nguyen
    Kolluri, Nikhil
    Muschen, Markus
    Grant, Steven
    CLINICAL CANCER RESEARCH, 2011, 17 (10) : 3219 - 3232
  • [10] NK cells are diminished in CML, progressively replaced by BCR/ABL+ NK cells, and CD34+ BCR/ABL+ progenitors exhibit a partial block in NK cell differentiation.
    Miller, JS
    Ward, J
    Dolan, M
    Oseth, L
    Hirsch, B
    BLOOD, 1999, 94 (10) : 532A - 532A